Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Phase 2 Terminated 249 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer. PURPOSE: This phase II trial is studying an individualized drug treatment selection process, based on laboratory results, for treating patients with pancreatic cancer that can be removed by surgery.

Timeline

Start: 2005-10
Primary completion: 2010-04
Completion: 2010-04

Publications

Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011 Jan;10(1):3-8. doi: 10.1158/1535-7163.MCT-10-0893. Epub 2010 Dec 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1.5 unknown	Oral
Subject	Cetuximab	Monoclonal antibody	500 mg	Other
Subject	Docetaxel	Small molecule	20 mg/kg	Intravenous
Subject	Erlotinib	Small molecule	75 mg/kg	Other
Subject	Gemcitabine	Small molecule	100 mg/kg	Other
Subject	Irinotecan	Small molecule	50 mg/kg	Intravenous
Subject	Mitomycin C	Other / unclassified	5 mg/kg	Other
Subject	Sirolimus	Small molecule	4 mg/kg	Other

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications